When was Ascentage Pharma founded?

Ascentage Pharma was founded in 2009 and raised its 1st funding round 15 years after it was founded.

Where is Ascentage Pharma located?

Ascentage Pharma is headquartered in Suzhou, China. It is registered at Rockville, Maryland.

Who is the current CEO of Ascentage Pharma?

Dajun Yang of Ascentage Pharma. They have also founded 1 company.

How many employees does Ascentage Pharma have?

As of Dec 31, 2022, the latest employee count at Ascentage Pharma is 97.

Is Ascentage Pharma a funded company?

Ascentage Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Jun 20, 2024.

When was the latest funding round of Ascentage Pharma?

Ascentage Pharma's latest funding was a $***** Post IPO round on Jun 20, 2024, with participation from 1 investor.

Where does Ascentage Pharma rank among its competitors?

Ascentage Pharma ranks 379th amongst 3321 active competitors, of which 1132 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Ascentage Pharma?

Ascentage Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Ascentage Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics to treat cancer and other diseases. The company focuses on developing therapeutics that inhibit protein interactions to restore apoptosis, or programmed cell death. The company develops pipeline of therapeutics for cancers, chronic hepatitis B, and age-related diseases.

Website: ascentage.com
Email ID: *****@ascentage.com
Phone Number: +86 **********
Registered Address: Rockville, Maryland

Key Metrics

Founded Year

2009

Location

Suzhou, China

Stage

Public

Latest Funding Round

Post IPO, Jun 20, 2024, $*****

Investors

Takeda & 1 more

Ranked

379^th among 3321 active competitors

Employee Count

97 as on Dec 31, 2022

Similar Companies

BeiGene & 621 more

Exit Details

Public

View Ascentage Pharma's full profile

Ascentage Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ASCENTAGE PHARMA GROUP INC. CIN: 811034123 , United States, Active	Dec 26, 999	-	87 (As on Dec 31, 2024)	-

Ascentage Pharma got listed on Oct 28, 2019.

Click here to take a look at Ascentage Pharma's IPO in detail

Ascentage Pharma has raised funding over 1 round. Its latest funding round was a Post IPO round on Jun 20, 2024 for $*****. 1 investor participated in its latest round. Ascentage Pharma has 2 institutional investors.

Here is the list of recent funding rounds of Ascentage Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 20, 2024	3642847	Post IPO	4997282	6929013	1009891	5424399

Access funding benchmarks and valuations. Sign up today!

View details of Ascentage Pharma's funding rounds and investors

The founders of Ascentage Pharma are Dajun Yang and Shaomeng Wang. Dajun Yang is the CEO of Ascentage Pharma.

Here are the details of Ascentage Pharma's key team members:

Dajun Yang: Co-Founder & CEO of Ascentage Pharma.
Contact Info: 1 email address
Shaomeng Wang: Co-Founder of Ascentage Pharma.
Contact Info: 1 email address

View details of Ascentage Pharma's Founder profiles and Board Members

Ascentage Pharma's employee count trend

Ascentage Pharma has 97 employees as of Dec 22. The total employee count is 39.0% more than what it was in Dec 21. Here is Ascentage Pharma's employee count trend over the years:

Employee count trend for Ascentage Pharma

Uncover Ascentage Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ascentage Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Ascentage Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
379th	Ascentage Pharma 2009, Suzhou (China), Public	Developer of therapeutics to treat cancer and other diseases	-	Takeda, Oriza Holdings	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Ascentage Pharma's competitors? Click here to see the top ones

Ascentage Pharma has made no investments or acquisitions yet.

Media has covered Ascentage Pharma for a total of 25 events in the last 1 year, 15 of them have been about company updates and 1 about people movement.